News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,470 Results
Type
Article (214)
Company Profile (1)
Press Release (1255)
Section
Business (525)
Career Advice (1)
Deals (42)
Drug Delivery (1)
Drug Development (346)
FDA (25)
Job Trends (29)
News (908)
Policy (45)
Tag
Academia (1)
Alliances (84)
Antibody-drug conjugate (ADC) (1)
Approvals (26)
Artificial intelligence (4)
Bankruptcy (1)
Best Places to Work (19)
Biosimilars (1)
Biotechnology (1)
Bladder cancer (1)
Breast cancer (1)
Cancer (26)
Career advice (1)
Clinical research (302)
Collaboration (2)
COVID-19 (7)
C-suite (3)
Data (11)
Denatured (3)
Diagnostics (1)
Drug pricing (1)
Earnings (230)
Events (318)
Executive appointments (2)
FDA (30)
Funding (1)
Gene therapy (1)
GLP-1 (1)
Government (7)
Guidances (2)
Healthcare (14)
Immuno-oncology (1)
Infectious disease (7)
IPO (17)
Job creations (10)
Job search strategy (1)
Kidney cancer (4)
Layoffs (3)
Legal (6)
Liver cancer (1)
Lung cancer (3)
Lymphoma (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (26)
NextGen: Class of 2025 (5)
Non-profit (2)
Opinion (6)
Pancreatic cancer (1)
Patents (1)
People (224)
Phase I (117)
Phase II (94)
Phase III (153)
Pipeline (6)
Postmarket research (2)
Preclinical (19)
Prostate cancer (3)
Real estate (5)
Regulatory (44)
Research institute (2)
Series B (1)
Special edition (1)
Startups (1)
The Weekly (1)
Date
Today (1)
Last 7 days (1)
Last 30 days (10)
Last 365 days (66)
2025 (58)
2024 (66)
2023 (101)
2022 (118)
2021 (118)
2020 (96)
2019 (64)
2018 (70)
2017 (92)
2016 (81)
2015 (68)
2014 (50)
2013 (36)
2012 (53)
2011 (66)
2010 (49)
Location
Africa (4)
Asia (38)
Australia (6)
California (42)
Canada (1)
China (1)
Connecticut (1)
Europe (178)
Maryland (1)
Massachusetts (1)
New Jersey (1)
New York (2)
Northern California (24)
Pennsylvania (1)
South America (4)
Southern California (11)
United States (51)
Washington State (1)
Wisconsin (1)
1,470 Results for "exelixis".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
October 21, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Exelixis Lays Off 130 as Pennsylvania Site Closes Down
Exelixis is looking at the possibility of relocating some of the eliminated Pennsylvania roles to its headquarters in Alameda, California, according to a company spokesperson.
August 28, 2025
·
2 min read
·
Tristan Manalac
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
·
1 min read
Press Releases
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2025
August 28, 2025
·
2 min read
Press Releases
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 17, 2025
·
3 min read
Pipeline
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for the second half of 2025.
February 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
September 1, 2025
·
4 min read
Press Releases
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
October 20, 2025
·
19 min read
Press Releases
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
July 28, 2025
·
20 min read
1 of 147
Next
